Predicted cross-reactivity based on sequence identity: Gorilla (100%), Gibbon (100%), Marmoset (95%), Hamster (84%), Canine (84%).
Packaging, Storage & Formulations
Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
0.1% Sodium Azide
Immunogen affinity purified
Alternate Names for GPR1 Antibody
G protein-coupled receptor 1
probable G-protein coupled receptor 1
GPR1 is an Orphan-A GPCR with an unknown ligand. GPR1 was identified in a search for genes responsible for mediating brain reward and may have a role in drug addiction. It has also been shown to act as an HIV coreceptor in kidney mesangial cells (Tokizawa et al., 2000). GPR1 has been reported to be expressed in brain and kidney. ESTs have been isolated from placenta and thymus libraries. Caution: GPR1 should be distinguished from the yeast protein of the same name.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.
Review this Product
Be the first to review our GPR1 Antibody and receive a gift card or discount.
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.